Danish healthcare giant Novo Nordisk is this week inaugurating a new pilot plant for the development and production of new biopharmaceuticals based on proteins cultured in mammalian cells. Novo Nordisk has three key business areas: diabetes care, haemostasis management and growth hormone therapy. The strategy with the new facility is to strengthen the company's position in haemostasis management while also enabling the company to add a fourth key business area – immunotherapy.
The new pilot plant, which cost approx. DKK 350 m (USD 63 m), is an extension of Novo Nordisk’s existing production facility in Hillerød north of Copenhagen, and contains development laboratories and production facilities. Today Novo Nordisk’s commercial production of biopharmaceuticals is based on three different types of cells: yeast, E. coli and mammalian cells.
Novo Nordisk executive vice president and chief scientific officer Mads Krogsgaard Thomsen, comments: “This new pilot plant underlines Novo Nordisk’s strong commitment to biopharmaceuticals, both in existing areas such as haemostasis, and new areas such as inflammation and cancer. It will significantly increase our capacity for producing investigational compounds for clinical trials.”
The first compounds to be produced by the new facility will be antibodies against cancer. The inflammation area could also provide major immunotherapy market opportunities for Novo Nordisk in conditions such as rheumatoid arthritis and psoriasis.
Headquartered in Denmark, Novo Nordisk is a world leader in diabetes care. The company employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London.
The news was reported by national daily newspaper Berlingske Tidende and on Novo Nordisk's website